Bicara Therapeutics (BCAX) Share-based Compensation (2023 - 2026)

Bicara Therapeutics' Share-based Compensation history runs 3 years deep, the most recent figure standing at $5.9 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 69.75% year-over-year to $5.9 million; the TTM figure through Mar 2026 stood at $4.3 million (down 55.83% YoY), while the FY2025 annual figure was $1.9 million, down 74.61% from the prior year.
• Share-based Compensation for Q1 2026 stood at $5.9 million, up from -$8.7 million in the prior quarter.
• The five-year high for Share-based Compensation was $7.4 million in Q4 2024, with the low at -$8.7 million in Q4 2025.
• The 3-year median for Share-based Compensation is $3.5 million (2025), against an average of $1.9 million.
• Peak annual rise in Share-based Compensation reached 404.45% in 2025, while the deepest fall reached 217.33% in 2025.
• Bicara Therapeutics' Share-based Compensation stood at $7.4 million in 2024, then plunged by 217.33% to -$8.7 million in 2025, then soared by 167.5% to $5.9 million in 2026.
• Business Quant data shows BCAX's Share-based Compensation at $5.9 million in Q1 2026, -$8.7 million in Q4 2025, and $3.6 million in Q3 2025.